CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

205103Orig1s000

CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

NDA: 205103	Submission Date(s): 03/14/2016, 5/2/2016, 7/20/2016
Submission Type; Code	Resubmission
Brand Name	Yosprala
Generic Name	Aspirin Delayed Release/Omeprazole Immediate Release
Reviewer	Dilara Jappar, Ph.D.
Team Leader	Sue-Chih Lee, Ph.D.
OCP Division	Division of Clinical Pharmacology 3
OND Division	Division of Gastroenterology and Inborn Errors Products
	(DGIEP)
Sponsor	POZEN, Inc
Formulation; Strength(s)	Tablet, 81 mg or 325 mg Aspirin/40 mg Omeprazole
Proposed Indication	Use in the secondary prevention of cardiovascular and
	cerebrovascular events in patients at risk of developing
	aspirin-associated gastric ulcers
Proposed Dosing Regimen	Once Daily tablet
PDUFA Goal Date:	09/14/2016

OFFICE OF CLINICAL PHARMACOLOGY REVIEW

Table of Contents

Table of Contents	1
1 Executive Summary	
1.1 Recommendation	2
1.2 Summary of Clinical Pharmacology and Biopharmaceutics Findings	2
2 Question Based Review	3
2.1 What are the differences in aspirin API from the two suppliers?	3
2.2 Is the aspirin (acetylsalicylic acid) component of Yosprala from the two suppliers bioequiv	
at the proposed dosages?	5
2.3 What is the relative bioavailability of omeprazole in PA8140 compared to reference pro	oduct
Prilosec?	10
3 Appendix	12
3.1 Individual reviews	

1 Executive Summary

This is a 505(b)(2) application for Yosprala (Delayed Release Aspirin/Immediate Release omeprazole) tablets referencing Ecotrin® (EC-Aspirin) and Prilosec® (EC-Omeprazole). The proposed product is an oral fixed dose combination product containing 81 mg or 325 mg aspirin in the inner enteric coated core (delayed release) surrounded by 40 mg omeprazole in the immediate-release film coat to release the active ingredients in a sequential fashion.

The original application was submitted on 03/25/2013. A full clinical pharmacology review was conducted during the 1st review cycle and application was acceptable from clinical pharmacology perspective. Please see Clinical Pharmacology review dated 04/18/2014. However, this application was issued a Complete Response (CR) action letter on 04/25/2014 due to facility inspection deficiencies at ^{(b)(4)} manufacturing facility, which was a supplier to aspirin drug substance used to manufacture Yosprala tablets. There were no deficiencies from clinical pharmacology perspective.

The sponsor submitted a response to the Complete Response action letter (resubmission) on June 30, 2014. There was no new clinical pharmacology study in that submission. Please see clinical pharmacology review dated 11/24/2014. That submission was issued another Complete Response (CR) action letter on 12/16/2014 due to facility inspection deficiencies at aspirin substance supplier ^{(b) (4)} manufacturing facility again.

In this 3rd submission, the sponsor submitted another response to Complete Response action letter (resubmission) on March 14, 2016. In this submission, in order to address its manufacturing facility deficiency, the sponsor had changed the supplier for aspirin component from the previous supplier (b)(4) (also referred to as (b)(4)) (b)(4) The omeprazole for Yosprala Tablets and the manufacturing process for Yosprala Tablets remain completely unchanged. To support these changes in aspirin supplier, in addition to in-vitro testing, the sponsor submitted two relative BA/BE study comparing the aspirin components of PA32540 and PA8140 (b)(4)

1.1 Recommendation

The application is acceptable from the clinical pharmacology perspective provided that a mutual agreement is reached on the labeling languages.

1.2 Summary of Clinical Pharmacology and Biopharmaceutics Findings

Aspirin Supplier Comparison: In this submission, the sponsor changed API aspirin supplier source from ^{(b)(4)} to (also referred to as ^{(b)(4)}). In addition, aspirin

BA/BE study:

Aspirin components of PA8140 and PA32540 from the new supplier ^{(b)(4)} was bioequivalent to that of previous supplier ^{(b)(4)} based on two separate BE studies (PA8140-104 and PA32540-119) that had used partial reference-replicate3-way study design with a reference-scaled average BE approach.

OSI inspection:

An inspection for bioequivalence (BE) studies PA8140-104 and PA32540-119 for both clinical site and bioanalytical site was requested on 06/21/2016. However, the Division of New Drug Bioequivalence Evaluation (DNDBE) within the Office of Study Integrity and Surveillance (OSIS) recommends accepting data without an on-site inspection (b)(4) as OSIS recently inspected these sites and the inspectional outcome from the inspections was classified as No Action Indicated (NAI).

Relative BA of omeprazole component of PA8140 vs Prilosec :

Based on bridged cross-study comparisons, the plasma exposure of IR omeprazole 40 mg from PA8140 was lower than that of Prilosec 40 mg, Prilosec[®]. Cmax and AUC of IR omeprazole 40 mg from PA8140 were estimated to be 90% and 75%, respectively, of that from an EC formulation omeprazole 40 mg, Prilosec 40 mg following a repeat dose administration for 7 days.

2 Question Based Review

2.1 What are the differences in aspirin API from the two suppliers? In this submission, the sponsor changed API aspirin supplier source from (b)(4) to (also referred to as (b)(4)). In addition, aspirin from this new supplier Table 1: Comparison of ASA (b)(4) Sourced From (b)(4) (b)(4) (New Source) (b)(4)

Table 2: Comparison of PA8140 Aspirin Core Tablet Formulation

(b) (4)

Components	Quantity per unit (mg/tablet)

Find authenticated court documents without watermarks at docketalarm.com.




Table 3: Comparison of PA32540 Aspirin Core Tablet Formulation

(b) (4)



DOCKET Α LARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.